Predictors of Survival in Esophageal Squamous Cell Carcinoma with Pathologic Major Response after Neoadjuvant Chemoradiation Therapy and Surgery: The Impact of Chemotherapy Protocols

Table 1

Characteristics of 117 patients stratified by disease progression.

Subgroup	Total	Disease progression; (percentage)	Nonprogression; (percentage)	P value
Age
<60 y	66	38 (57.6)	28 (42.4)	0.316
≥60 y	51	34 (66.7)	17 (32.3)
Gender
Male	107	67 (62.6)	40 (37.4)	0.505
Female	10	5 (50.0)	5 (50.05)
T staging
0, 1, 2	107	64 (59.8)	43 (40.2)	0.313
3, 4	10	8 (80.0)	2 (20.02)
CCRT response
pCR	67	40 (59.7)	27 (40.3)	0.636
MRD	50	32 (64.0)	18 (36.0)
CCRT regimen
PF	50	39 (78.0)	11 (22.0)	0.002
Taxane-incorporated CCRT	67	33 (49.3)	34 (50.7)

value from test or Fisher’s exact test where the value is <0.05.
Post-CCRT pathologic T staging.
pCR: pathologic complete response; MRD: microscopic residual disease.
Taxane-incorporated CCRT: modified TPFL or TP-HDFL and then neoadjuvant CCRT (TP regimen), or the standard neoadjuvant CCRT with TP regimen.